Publication date: Available online 31 October 2026 Source: Clinical Microbiology and Infection Author(s): Fernando G. Zampieri, Israel S. Maia, Alexandra Spicer
Clinical heterogeneity and average treatment effects: consequences for superiority and non-inferiority trials. // Clinical Microbiology and Infection. – URL: https://www.sciencedirect.com/science/article/pii/S1198743X26006075?dgcid=rss_sd_all
Clinical heterogeneity and average treatment effects: consequences for superiority and non-inferiority trials. Clinical Microbiology and Infection. https://www.sciencedirect.com/science/article/pii/S1198743X26006075?dgcid=rss_sd_all
“Clinical heterogeneity and average treatment effects: consequences for superiority and non-inferiority trials.” Clinical Microbiology and Infection.
@article{article88835,
title = {Clinical heterogeneity and average treatment effects: consequences for superiority and non-inferiority trials},
journal = {Clinical Microbiology and Infection},
url = {https://www.sciencedirect.com/science/article/pii/S1198743X26006075?dgcid=rss_sd_all}
}
ABSTRACT Background Aspergillus fumigatus can cause life‐threatening infections, primarily treated with azole antifungals. Azole‐resistant A. fumigatus (ARAF) is a major clinical concern. Environmental resistance development is an...
ABSTRACT Background The lipid‐dependent yeast genus Malassezia is composed of skin commensals that can become pathogenic. This genus can cause bloodstream infection in low‐weight preterm neonates and immunocompromised adults. However,...